Brincidofovir is a prodrug of the acyclic nucleoside phosphonate cidofovir, which is converted to cidofovir in human lung fibroblasts (MRC-5). It effectively inhibits replication of CMV, HSV-1, HSV-2, cowpox, and vaccinia viruses, with EC50 values ranging from 0.0009 to ~1 µM. Brincidofovir also reduces mortality in mouse models of cowpox and vaccinia infections at doses of 6.7 and 5 mg/kg, respectively.
Usually ships within 24 hours.